Live Breaking News & Updates on International Breast Cancer Research Committee

Stay updated with breaking news from International breast cancer research committee. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Tecentriq Plus Perjeta, Chemo Does Not Improve pCR in HER2+ Breast Cancer

A recent phase 3 APTneo Michelangelo trial added Tecentriq to neoadjuvant Herceptin plus Perjeta and chemotherapy which did not lead to a statistically significant improvement in pathologic complete response in patients with HER2-positive operable breast cancer. ....

San Antonio , United States , Luca Gianni , Antonio Breast Cancer , International Breast Cancer Research Committee , Fondazione Michelangelo , Breast Cancer ,

Atezolizumab Plus Neoadjuvant HP/Chemo Does Not Significantly Improve pCR in HER2+ Breast Cancer

The addition of atezolizumab to neoadjuvant trastuzumab plus pertuzumab (HP) and chemotherapy led to a numerical, but not statistically significant, increase in pathologic complete response vs HP/chemotherapy alone in patients with HER2-positive operable breast cancer. ....

San Antonio , United States , Menarini Ricerche , Aptneo Michelangelo , Luca Gianni , Biomedical Insights Inc , Denali Therapeutics Inc , Artemida Pharma Ltd , Antonio Breast Cancer , International Breast Cancer Research Committee , Fondazione Michelangelo , Revolution Medicines , European Patent Application , Atezolizumab Plus Hp And Chemotherapy , Pertuzumab And Trastuzumab , Her2 Positive Breast Cancer , Aptneo Michelangelo Trial , San Antonio Breast Cancer Symposium , Pathologic Complete Response ,